Mirati Therapeutics, Inc.
KRas G12C inhibitors
Last updated:
Abstract:
The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
Status:
Grant
Type:
Utility
Filling date:
14 May 2019
Issue date:
12 May 2020